Pfizer reports positive Phase 2 infant data for next-gen pneumococcal vaccine
Share
Pfizer (NYSE:PFE) disclosed preliminary data from its Phase 2 clinical trial evaluating PF-07872412, an investigational 25-valent pneumococcal conjugate vaccine candidate designed for pediatric use.
